INDP

+ Watchlist + Portfolio

Indaptus Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.12
52-Week Range: $0.92 – $5.96
Market Cap: $317.12M
P/E (TTM): —
EPS (TTM): -6.15
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 28.00
PEG Ratio: —
Return on Equity: -318.04%
Return on Assets: -98.08%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 19.48
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-9.67M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $305.56M

INDP Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$6.32M	$7.62M	$7.25M	$9.34M
Selling, General & Admin	$8.59M	$8.76M	$8.11M	$10.49M
Operating Expenses	$14.91M	$16.38M	$15.37M	$19.83M
Operating Income	-$14.91M	-$16.38M	-$15.37M	-$19.83M
EBITDA	-$14.91M	-$16.38M	-$15.37M	-$19.83M
Pretax Income	-$14.32M	-$15.42M	-$15.02M	-$20.85M
Net Income	-$14.32M	-$15.42M	-$15.02M	-$20.85M
Diluted EPS	-48.44	-51.24	-45.08	-21.58
Diluted Shares	295075	300037	334132	966124

INDP Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$9.63M	$13.36M	$5.79M	$8.51M
Receivables	$0.00	—	—	—
Current Assets	$27.24M	$14.00M	$6.62M	$9.31M
Total Assets	$28.06M	$14.92M	$7.34M	$9.31M
Current Liabilities	$3.43M	$2.77M	$3.39M	$6.16M
Total Debt	$80.49K	$175.05K	$84.16K	$0.00
Total Liabilities	$3.43M	$2.85M	$3.39M	$6.16M
Retained Earnings	-$29.99M	-$45.42M	-$60.44M	-$81.29M
Shareholders' Equity	$24.63M	$12.08M	$3.94M	$3.15M
Working Capital	$23.81M	$11.22M	$3.22M	$3.15M

INDP Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.08M	-$13.41M	-$12.32M	-$14.82M
Free Cash Flow	-$13.08M	-$13.41M	-$12.32M	-$14.82M
Depreciation & Amortisation	$1.78K	$1.28K	$735.00	$0.00
Stock-Based Compensation	$2.96M	$2.97M	$2.31M	$1.36M
Investing Cash Flow	-$16.43M	$17.14M	$0.00	—
Financing Cash Flow	$0.00	$0.00	$4.75M	$17.54M
Net Change in Cash	-$29.51M	$3.74M	-$7.58M	$2.72M

INDP Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.81M	$2.17M	$1.52M	$2.85M	$491.13K	$363.13K
Selling, General & Admin	$1.76M	$2.29M	$1.13M	$5.31M	$1.67M	$1.45M
Operating Expenses	$4.57M	$4.46M	$2.65M	$8.16M	$2.16M	$1.81M
Operating Income	-$4.57M	-$4.46M	-$2.65M	-$8.16M	-$2.16M	-$1.81M
EBITDA	-$4.57M	-$4.46M	-$2.65M	-$8.16M	-$2.16M	-$1.81M
Pretax Income	-$4.53M	-$5.23M	-$2.98M	-$8.11M	-$2.54M	-$1.79M
Net Income	-$4.53M	-$5.23M	-$2.98M	-$8.11M	-$2.54M	-$1.79M
Diluted EPS	-9.11	-9.09	-2.98	—	-0.23	-0.02
Diluted Shares	497794	574923	997038	—	10.96M	116.13M

INDP Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$3.89M	$6.16M	$5.83M	$8.51M	$1.50M	$7.55M
Current Assets	$4.96M	$6.41M	$6.44M	$9.31M	$2.18M	$11.99M
Total Assets	$5.41M	$6.84M	$6.84M	$9.31M	$2.18M	$11.99M
Current Liabilities	$2.61M	$8.51M	$2.23M	$6.16M	$933.00K	$615.43K
Total Debt	$59.51K	$6.54M	$8.69K	$0.00	—	—
Total Liabilities	$2.61M	$8.51M	$2.23M	$6.16M	$933.00K	$615.43K
Retained Earnings	-$64.97M	-$70.20M	-$73.18M	-$81.29M	-$83.83M	-$85.62M
Shareholders' Equity	$2.80M	-$1.67M	$4.61M	$3.15M	$1.25M	$11.37M
Working Capital	$2.35M	-$2.10M	$4.20M	$3.15M	$1.25M	$11.37M
Net Debt	—	$344.80K	—	—	—	—

INDP Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.05M	-$4.02M	-$2.57M	-$3.19M	-$7.01M	-$1.93M
Free Cash Flow	-$5.05M	-$4.02M	-$2.57M	-$3.19M	-$7.01M	-$1.93M
Depreciation & Amortisation	$0.00	$0.00	$0.00	$0.00	—	—
Stock-Based Compensation	$240.89K	$180.76K	$150.61K	$785.81K	$227.18K	-$64.28K
Financing Cash Flow	$3.15M	$6.28M	$2.24M	$5.87M	$0.00	$11.98M
Net Change in Cash	-$1.90M	$2.27M	-$332.06K	$2.68M	-$7.01M	$6.06M

Market Snapshot

About

Indaptus Therapeutics, Inc. is a pre-clinical stage biotechnology company developing novel therapeutics for cancer treatment. The company's approach focuses on targeting the tumor microenvironment and cancer metabolism to disrupt cancer cell survival mechanisms. Indaptus is advancing its lead programs through preclinical development with the goal of initiating clinical trials. The company's technology platform aims to identify and exploit cancer-specific vulnerabilities that can be addressed with small molecule or biologic therapies.